The future of frontline immunotherapy in ALL: blinatumomab, inotuzumab ozogamicin, and CAR-Ts [Video]

Mark Litzow, MD, Mayo Clinic Rochester, Rochester, MN, discusses the future of immunotherapy in earlier lines of treatment for patients with acute lymphoblastic leukemia (ALL). Following positive results from the ECOG-E1910 trial (NCT02003222) evidencing early treatment with blinatumomab, as well as trials showing the efficacy of inotuzumab ozogamicin, Dr Litzow anticipates a shift towards greater reliance on immunotherapy in frontline treatments, reducing dependence on chemotherapy. He also highlights the integration of CAR-T therapies into the frontline setting. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.